CN1233413C - Nano particle feeding system for oral use - Google Patents
Nano particle feeding system for oral use Download PDFInfo
- Publication number
- CN1233413C CN1233413C CN 02153918 CN02153918A CN1233413C CN 1233413 C CN1233413 C CN 1233413C CN 02153918 CN02153918 CN 02153918 CN 02153918 A CN02153918 A CN 02153918A CN 1233413 C CN1233413 C CN 1233413C
- Authority
- CN
- China
- Prior art keywords
- drug
- supplying system
- ciclosporin
- enteric
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 48
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 67
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 65
- 238000003756 stirring Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 208000035126 Facies Diseases 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 7
- 229920001993 poloxamer 188 Polymers 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 6
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- -1 phthalate ester Chemical class 0.000 claims description 4
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 abstract description 36
- 229960001265 ciclosporin Drugs 0.000 abstract description 21
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 2
- 230000031891 intestinal absorption Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000002195 soluble material Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000009593 lumbar puncture Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002539 nanocarrier Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153918 CN1233413C (en) | 2002-12-05 | 2002-12-05 | Nano particle feeding system for oral use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153918 CN1233413C (en) | 2002-12-05 | 2002-12-05 | Nano particle feeding system for oral use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1418703A CN1418703A (en) | 2003-05-21 |
CN1233413C true CN1233413C (en) | 2005-12-28 |
Family
ID=4752401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02153918 Expired - Lifetime CN1233413C (en) | 2002-12-05 | 2002-12-05 | Nano particle feeding system for oral use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1233413C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101836958B (en) * | 2009-03-20 | 2012-10-03 | 北京大学 | Preparation of taxane pH sensitive nanoparticles composite for oral administration and application thereof |
-
2002
- 2002-12-05 CN CN 02153918 patent/CN1233413C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1418703A (en) | 2003-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Simos et al. | Trends of nanotechnology in type 2 diabetes mellitus treatment | |
CN1625391A (en) | Cyclosporin-containing sustained release pharmaceutical composition | |
JP5384831B2 (en) | Nanoparticles for protein drug delivery | |
Simon-Yarza et al. | Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia | |
CN1503662A (en) | Pharmaceutical preparation | |
CN1610538A (en) | Microemulsion preconcentrate | |
CN101366697A (en) | Novel nano-lipid carrier for injection embodying paclitaxel series substances and preparation method thereof | |
US8859004B2 (en) | pH-sensitive nanoparticles for oral insulin delivery | |
Wu et al. | Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery | |
CN1872072A (en) | Nano emulsion injection of alprostadil and preparation method | |
CN1148224C (en) | Cyclosporin containing composition and process for preparation | |
CN1732918A (en) | Nanometer preparation of silybin and preparation method thereof | |
Soudry-Kochavi et al. | Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles | |
EP3411019A1 (en) | Oral dosage form with drying agent for delivery of active agent | |
Peng et al. | Implantable sandwich PHBHHx film for burst-free controlled delivery of thymopentin peptide | |
CN103977407A (en) | Oral nanoparticle polypeptide composition tablets and preparation method thereof | |
AU5449399A (en) | Long time drug-sustained release preparation | |
CN104027793A (en) | Preparation method and application of nerve growth factor controlled-release nano-carrier | |
CN101317832B (en) | Oral administration nano-drug administration system of resveratrol | |
CN100335134C (en) | Nimodipine soft capsule and its prepn | |
CN1233413C (en) | Nano particle feeding system for oral use | |
CN1791390A (en) | Oral sustained release pharmaceutical composition | |
EP1924248A1 (en) | Ph sensitive nanoparticle formulation for oral delivery of proteins/peptides | |
CN101810560B (en) | Cyclosporine A polymeric micelles composition | |
CN101675995A (en) | 10-hydroxycamptothecinreagent-delivery lipid ultrasound microbubble agent and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: NCPC GENETECH BIOTECHNOLOGY DEVELOPMENT CO.,LTD. Assignor: NORTH CHINA PHARMACEUTICAL Group Corp. Contract fulfillment period: 2008.10.7 to 2013.10.7 Contract record no.: 2008130000021 Denomination of invention: Nano particle feeding system for oral use Granted publication date: 20051228 License type: Exclusive license Record date: 20081022 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: NCPC GENETECH BIOTECHNOLOGY DEVELOPMENT CO.,LTD. Assignor: NORTH CHINA PHARMACEUTICAL Group Corp. Contract fulfillment period: 2008.10.7 to 2013.10.7 Contract record no.: 2008130000021 Denomination of invention: Nano particle feeding system for oral use Granted publication date: 20051228 License type: Exclusive license Record date: 20081022 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.7 TO 2013.10.7; CHANGE OF CONTRACT Name of requester: NORTH CHINA PHARMACUETICAL JINTAN BIOTECHNOLOGY CO Effective date: 20081022 |
|
ASS | Succession or assignment of patent right |
Owner name: HUABEI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HUABEI PHARMACEUTICAL GROUP CO., LTD. Effective date: 20140923 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050015 SHIJIAZHUANG, HEBEI PROVINCE TO: 050000 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140923 Address after: 050000 No. 115, Hainan Road, Shijiazhuang economic and Technological Development Zone, Shijiazhuang, Hebei Patentee after: NORTH CHINA PHARMACEUTICAL Co.,Ltd. Address before: 050015 Heping East Road, Hebei, Shijiazhuang, No. 388 Patentee before: NORTH CHINA PHARMACEUTICAL Group Corp. |
|
CX01 | Expiry of patent term |
Granted publication date: 20051228 |
|
CX01 | Expiry of patent term |